Literature DB >> 8781568

Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions.

T Papp1, M Jafari, D Schiffmann.   

Abstract

In this study we analysed snap-frozen surgical resections of 16 superficial spreading melanomas, 13 nodular malignant melanomas, 2 lentigo maligna melanomas, 1 dysplastic nevus, 1 congenital nevus and 5 normal nevi from 38 patients for point mutations in the human p53 gene at exons 5-8 by polymerase chain reaction/single-strand conformation polymorphism as well as for loss of heterozygosity of p53 by restriction-fragment-length polymorphism/polymerase chain reaction in order to determine whether p53 aberrations are associated with melanoma subtypes. In addition, we analysed six melanoma cell lines for point mutations in p53. Our results revealed the absence of point mutations and loss of heterozygosity in all fresh resected lesions. However, a TAC (Tyr) to TGC (Cys) transition at codon 163 in exon 5 was found in one cell line.

Entities:  

Mesh:

Year:  1996        PMID: 8781568     DOI: 10.1007/bf01213550

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  51 in total

1.  Cancer. A deadly inheritance.

Authors:  B Vogelstein
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  AccII polymorphism of the p53 gene.

Authors:  O de la Calle-Martín; V Fabregat; M Romero; J Soler; J Vives; J Yagüe
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

5.  Amplification of a gene encoding a p53-associated protein in human sarcomas.

Authors:  J D Oliner; K W Kinzler; P S Meltzer; D L George; B Vogelstein
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

6.  Mutation and expression of the p53 gene in human malignant melanoma.

Authors:  A P Albino; M J Vidal; N S McNutt; C R Shea; V G Prieto; D M Nanus; J M Palmer; N K Hayward
Journal:  Melanoma Res       Date:  1994-02       Impact factor: 3.599

Review 7.  Genotoxicity of singlet oxygen.

Authors:  B Epe
Journal:  Chem Biol Interact       Date:  1991       Impact factor: 5.192

8.  Analysis of p53 in human cutaneous melanoma cell lines.

Authors:  X Montano; M Shamsher; P Whitehead; K Dawson; J Newton
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

9.  Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53.

Authors:  T Soussi; C Caron de Fromentel; M Méchali; P May; M Kress
Journal:  Oncogene       Date:  1987-03       Impact factor: 9.867

10.  TP53 allele loss, mutations and expression in malignant melanoma.

Authors:  V A Flørenes; T Oyjord; R Holm; M Skrede; A L Børresen; J M Nesland; O Fodstad
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

View more
  14 in total

1.  Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Authors:  N Bardeesy; B C Bastian; A Hezel; D Pinkel; R A DePinho; L Chin
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

Review 2.  Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells.

Authors:  Yunyi Kong; Suresh M Kumar; Xiaowei Xu
Journal:  Arch Pathol Lab Med       Date:  2010-12       Impact factor: 5.534

Review 3.  Molecular aspects of melanocytic dysplastic nevi.

Authors:  Mahmoud Rezk Abd-Elwahed Hussein; Gary Stewart Wood
Journal:  J Mol Diagn       Date:  2002-05       Impact factor: 5.568

Review 4.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

5.  p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Authors:  Tamara Terzian; Enrique C Torchia; Daisy Dai; Steven E Robinson; Kazutoshi Murao; Regan A Stiegmann; Victoria Gonzalez; Glen M Boyle; Marianne B Powell; Pamela M Pollock; Guillermina Lozano; William A Robinson; Dennis R Roop; Neil F Box
Journal:  Pigment Cell Melanoma Res       Date:  2010-12       Impact factor: 4.693

6.  Cooperative effects of INK4a and ras in melanoma susceptibility in vivo.

Authors:  L Chin; J Pomerantz; D Polsky; M Jacobson; C Cohen; C Cordon-Cardo; J W Horner; R A DePinho
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

7.  Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.

Authors:  T Papp; H Pemsel; R Zimmermann; R Bastrop; D G Weiss; D Schiffmann
Journal:  J Med Genet       Date:  1999-08       Impact factor: 6.318

Review 8.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

9.  High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays.

Authors:  Roland Houben; Sonja Hesbacher; Corinna P Schmid; Claudia S Kauczok; Ulrike Flohr; Sebastian Haferkamp; Cornelia S L Müller; David Schrama; Jörg Wischhusen; Jürgen C Becker
Journal:  PLoS One       Date:  2011-07-08       Impact factor: 3.240

10.  Nevus senescence.

Authors:  Andrew L Ross; Margaret I Sanchez; James M Grichnik
Journal:  ISRN Dermatol       Date:  2011-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.